After a cruel 2022, here are my views on this high-beta sector as we head into the new year.
It's hard to justify the high valuations for many growth issues when economic conditions around the globe are far from robust.
An unsettling secondary offering is reminiscent of Peloton's in the wake of its dramatic fall from the highs.
TINA (there is no alternative) is dateless, but her popular cousin CITA (cash is the alternative) is enjoying the prom.
Whether Thursday's bullish reversal in stocks was a bottom or just another tradable low is anyone's guess, so let's focus on Friday.
Small-caps and stocks that are part of the ARK Innovation ETF fared better than the big growth names on Friday and are worth watching this week.
ETF veteran Kevin Kelly is the force behind Kelly ETFs, which this month introduced three funds with distinctly different focuses.
Plus, many economists don't seem to understand the term "full employment" and earnings season kicks off.
Plus, the intersection of rising inflation and a slowing velocity of money give us reason for pause.
There are reasons to believe the shares of Dynavax Technologies and Eyenovia Inc. could do well in the months ahead.